NCT03094663View on ClinicalTrials.gov

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

September 1, 2018

Conditions
Knee Arthropathy
Interventions
DRUG

Bupivacaine with epinephrine

bupivacaine 0.5% with epinephrine 30cc

DRUG

Methylprednisolone

40 mg/ml, 1 ml

DRUG

Cefazolin

500 mg in 10 ml

DEVICE

8 MHz. Chiba needle

22G/ 4 inches

DRUG

Bupivacaine with Dexamethasone

15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone

DRUG

Bupivacaine 25cc

25 cc 0.25% bupivacaine

DRUG

Bupivacaine 20cc

20cc 0.25% bupivacaine

DRUG

Dexamethasone

2 mg IV dexamethasone.

Trial Locations (1)

10021

Hospital For Special Surgery, New York

All Listed Sponsors
lead

Hospital for Special Surgery, New York

OTHER

NCT03094663 - Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI) | Biotech Hunter | Biotech Hunter